SNNUF Quote, Financials, Valuation and Earnings

NuCana Plc has a net margin of -- compared to Smith & Nephew plc's net margin of --. Smith & Nephew plc's return on equity of 9.2% beat NuCana Plc's return on equity of -215.21%.

Smith & Nephew plc has a consensus price target of --, signalling downside risk potential of --. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 1275973.62%. Given that NuCana Plc has higher upside potential than Smith & Nephew plc, analysts believe NuCana Plc is more attractive than Smith & Nephew plc.

Smith & Nephew plc has a beta of 0.406, which suggesting that the stock is 59.4% less volatile than S&P 500. In comparison NuCana Plc has a beta of 1.791, suggesting its more volatile than the S&P 500 by 79.145%.

Smith & Nephew plc has a quarterly dividend of $0.24 per share corresponding to a yield of 2.44%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Smith & Nephew plc pays 53.43% of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend. Smith & Nephew plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Smith & Nephew plc quarterly revenues are --, which are smaller than NuCana Plc quarterly revenues of --. Smith & Nephew plc's net income of -- is lower than NuCana Plc's net income of -$3.3M. Notably, Smith & Nephew plc's price-to-earnings ratio is 22.42x while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew plc is 2.27x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.

Oxford Biomedica Plc has a net margin of -- compared to Smith & Nephew plc's net margin of --. Smith & Nephew plc's return on equity of 9.2% beat Oxford Biomedica Plc's return on equity of -120.93%.

Smith & Nephew plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Oxford Biomedica Plc has an analysts' consensus of -- which suggests that it could fall by --. Given that Smith & Nephew plc has higher upside potential than Oxford Biomedica Plc, analysts believe Smith & Nephew plc is more attractive than Oxford Biomedica Plc.

Smith & Nephew plc has a beta of 0.406, which suggesting that the stock is 59.4% less volatile than S&P 500. In comparison Oxford Biomedica Plc has a beta of 1.213, suggesting its more volatile than the S&P 500 by 21.298%.

Smith & Nephew plc has a quarterly dividend of $0.24 per share corresponding to a yield of 2.44%. Oxford Biomedica Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Smith & Nephew plc pays 53.43% of its earnings as a dividend. Oxford Biomedica Plc pays out -- of its earnings as a dividend. Smith & Nephew plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Smith & Nephew plc quarterly revenues are --, which are smaller than Oxford Biomedica Plc quarterly revenues of --. Smith & Nephew plc's net income of -- is lower than Oxford Biomedica Plc's net income of --. Notably, Smith & Nephew plc's price-to-earnings ratio is 22.42x while Oxford Biomedica Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew plc is 2.27x versus 3.58x for Oxford Biomedica Plc. Usually stocks with elevated PS ratios are considered overvalued.

Silence Therapeutics Plc has a net margin of -- compared to Smith & Nephew plc's net margin of -34617.65%. Smith & Nephew plc's return on equity of 9.2% beat Silence Therapeutics Plc's return on equity of -94.26%.

Smith & Nephew plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Silence Therapeutics Plc has an analysts' consensus of -- which suggests that it could fall by --. Given that Smith & Nephew plc has higher upside potential than Silence Therapeutics Plc, analysts believe Smith & Nephew plc is more attractive than Silence Therapeutics Plc.

Smith & Nephew plc has a beta of 0.406, which suggesting that the stock is 59.4% less volatile than S&P 500. In comparison Silence Therapeutics Plc has a beta of 0.736, suggesting its less volatile than the S&P 500 by 26.378%.

Smith & Nephew plc has a quarterly dividend of $0.24 per share corresponding to a yield of 2.44%. Silence Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Smith & Nephew plc pays 53.43% of its earnings as a dividend. Silence Therapeutics Plc pays out -- of its earnings as a dividend. Smith & Nephew plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Smith & Nephew plc quarterly revenues are --, which are smaller than Silence Therapeutics Plc quarterly revenues of $34K. Smith & Nephew plc's net income of -- is lower than Silence Therapeutics Plc's net income of -$11.8M. Notably, Smith & Nephew plc's price-to-earnings ratio is 22.42x while Silence Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew plc is 2.27x versus 506.96x for Silence Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.